Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

It’s a make or break year for GlaxoSmithKline. The UK’s largest pharmaceutical company is counting on a spate of drugs winning approval this year to reverse recent setbacks and revive growth.
Bloomberg